Related Experiment Video
Updated: Jan 2, 2026
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
Published on: September 28, 2018
Structural insights and binding analysis for determining the molecular bases for programmed cell death protein
Rita C Acúrcio1, Carlota Leonardo-Sousa1, Alfonso T García-Sosa2
1Research Institute for Medicines (iMed.ULisboa) , Faculty of Pharmacy , Universidade de Lisboa , 1649-003 Lisbon , Portugal .
Abstract:
Programmed cell death protein 1 (PD-1) and PD-ligand 1 (PD-L1) interaction plays an important role in cancer immunotherapy. Several PD-1/PD-L1 inhibitors have been approved with remarkable impact on overall patient survival rates. Inhibitors in clinical practice are presently limited to monoclonal antibodies. However, their severe shortcomings expose the need for a new generation of PD-L1 inhibitors. Understanding the tumor microenvironment, identifying specific biomarkers and X-ray crystalline structures of PD-1/PD-L1 complexes, including molecular and genomic signature studies are essential to determine the success for the development of PD-1/PD-L1 inhibitors into safer and efficient cancer immunotherapeutics. Currently, the development of immune-modulatory small molecules is being explored due to their benefits over recombinant protein approaches. Nevertheless, their development is hampered in part due to lack of structural information. The current study builds on PD-L1 small-molecule inhibitor structural information and provides insights into the design of new inhibitors. To this end, a comprehensive analysis of crystallographic structures and benchmarking studies were performed, showing the specific structure model and software best suited to study PD-L1. The use of in silico methodologies can give a deeper insight to guide the design of novel PD-L1 small-molecule inhibitors.
Insights
New research explores small molecule inhibitors targeting Programmed Cell Death-Ligand 1 (PD-L1) for cancer immunotherapy. Computational methods and structural analysis guide the design of safer, more effective PD-L1 inhibitors beyond current antibody treatments.
Area of Science:
- Immunology
- Oncology
- Structural Biology
Background:
- The interaction between Programmed Cell Death protein 1 (PD-1) and PD-Ligand 1 (PD-L1) is crucial in cancer immunotherapy.
- Current PD-1/PD-L1 inhibitors, primarily monoclonal antibodies, have limitations necessitating new therapeutic strategies.
- Small molecule inhibitors offer potential advantages over protein-based approaches but require structural insights for development.
Purpose of the Study:
- To provide structural insights for designing novel PD-L1 small-molecule inhibitors.
- To identify optimal computational methodologies for studying PD-L1 structure-inhibitor interactions.
- To advance the development of next-generation cancer immunotherapeutics.
Main Methods:
- Comprehensive analysis of crystallographic structures of PD-1/PD-L1 complexes.
- Benchmarking studies to determine the best structure models and software for PD-L1 analysis.
- Application of in silico methodologies for inhibitor design guidance.
Main Results:
- Identification of specific structural features relevant to PD-L1 inhibition.
- Validation of computational tools and models for structural studies of PD-L1.
- Demonstration of the utility of in silico approaches in guiding small-molecule inhibitor design.
Conclusions:
- Structural information is essential for developing effective PD-L1 small-molecule inhibitors.
- In silico methodologies can significantly aid in the rational design of novel cancer immunotherapeutics.
- This study provides a foundation for creating safer and more efficient PD-L1 inhibitors.
Related Concept Videos
02:40Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
01:31The Intrinsic Apoptotic Pathway
01:17The Extrinsic Apoptotic Pathway
01:30Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
02:04Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
02:26Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...